Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery

Pharmaceutical Research

Volumn 28, Issue 4, 2011, Pages 788-796

  Kwok, Philip Chi Lip ^a   Tunsirikongkon, Amolnat ^b   Glover, William ^c   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

aggregates; dispersion; lysozyme; nano matrix; roughness

Indexed keywords

2 PROPANOL; LYSOZYME; NANOPARTICLE;

ADHESION; AEROSOL; AQUEOUS SOLUTION; ARTICLE; DISPERSION; DRUG DELIVERY SYSTEM; INHALER; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; SPRAY DRYING; SURFACE PROPERTY;

2-PROPANOL; ADMINISTRATION, INHALATION; AEROSOLS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRY POWDER INHALERS; LIGHT; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, SCANNING; MURAMIDASE; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SCATTERING, RADIATION; SURFACE PROPERTIES;

EID: 79955603054     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0332-2     Document Type: Article

References (43)

1. H-K Chan 2006 Dry powder aerosol drug delivery-Opportunities for colloid and surface scientists Colloids Surf, A 284-285 50 5 10.1016/j.colsurfa.2005.10. 091 (Pubitemid 43870203)
2. JS Patton PR Byron 2007 Inhaling medicines: delivering drugs to the body through the lungs Nat Rev Drug Discov 6 67 74 17195033 10.1038/nrd2153 1:CAS:528:DC%2BD28XhtlGktbbL (Pubitemid 46020287)
3. Clark AR, Stevenson CL, Shire SJ. Formulation of proteins for pulmonary delivery. In: McNally EJ, Hastedt JE, editors. Protein formulation and delivery. New York: Informa Healthcare USA; 2008. p. 219-54.
4. Gonda I. Targeting by deposition. In: Hickey A, editor. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker; 2004. p. 65-88.
5. AJ Hickey HM Mansour MJ Telko Z Xu HDC Smyth T Mulder R McLean J Langridge D Papadopoulos 2007 Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics J Pharm Sci 96 1282 301 17455324 10.1002/jps.20916 1:CAS:528:DC%2BD2sXltVGqt74%3D (Pubitemid 46804582)
6. H-K Chan A Clark I Gonda M Mumenthaler C Hsu 1997 Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery Pharm Res 14 431 97 9144727 10.1023/A:1012035113276 1:CAS:528:DyaK2sXjtVWrsLg%3D (Pubitemid 27205000)
7. H-K Chan 2003 Inhalation drug delivery devices and emerging technologies Expert Opin Ther Pat 13 1333 43 10.1517/13543776.13.9.1333 1:CAS:528: DC%2BD3sXmslSiurY%3D (Pubitemid 37120883)
8. H Adi D Traini H-K Chan PM Young 2008 The influence of drug morphology on the aerosolisation efficiency of dry powder inhaler formulations J Pharm Sci 97 2780 8 17894369 10.1002/jps.21195 1:CAS:528:DC%2BD1cXotF2lsrs%3D
9. S Adi H Adi P Tang D Traini H-K Chan PM Young 2008 Micro-particle corrugation, adhesion and inhalation aerosol efficiency Eur J Pharm Sci 35 12 8 18586091 10.1016/j.ejps.2008.05.009 1:CAS:528:DC%2BD1cXpvF2ru7o%3D
10. NYK Chew H-K Chan 2001 Use of solid corrugated particles enhance powder aerosol performance Pharm Res 18 1570 7 11758765 10.1023/A:1013082531394 1:CAS:528:DC%2BD3MXos1ejsr8%3D (Pubitemid 33022413)
11. NYK Chew P Tang H-K Chan JA Raper 2005 How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res 22 148 52 15771241 10.1007/s11095-004-9020-4 1:CAS:528:DC%2BD2MXhtlClu7k%3D (Pubitemid 40558157)
12. PGA Rogueda D Traini 2007 The nanoscale in pulmonary delivery. Part 2: formulation platforms Expert Opin Drug Deliv 4 607 20 17970664 10.1517/17425247.4.6.607 1:CAS:528:DC%2BD2sXht1elsrvN (Pubitemid 350199199)
13. J Heyder J Gebhart G Rudolf CF Schiller W Stahlhofen 1986 Deposition of particles in the human respiratory tract in the size range 0.005-15 μm J Aerosol Sci 17 811 25 10.1016/0021-8502(86)90035-2 (Pubitemid 17492310)
14. N Tsapis D Bennett B Jackson DA Weitz DA Edwards 2002 Trojan particles: large porous carriers of nanoparticles for drug delivery Proc Natl Acad Sci 99 12001 5 12200546 10.1073/pnas.182233999 1:CAS:528:DC%2BD38XntlCltb4%3D
15. K Hadinoto K Zhu RBH Tan 2007 Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery Int J Pharm 341 195 206 17467934 10.1016/j.ijpharm.2007.03.035 1:CAS:528: DC%2BD2sXot1CmurY%3D (Pubitemid 47088103)
16. C Gómez-Gaete E Fattal L Silva M Besnard N Tsapis 2008 Dexamethasone acetate encapsulation into Trojan particles J Control Release 128 41 9 18374442 10.1016/j.jconrel.2008.02.008
17. Loebenberg R, Finlay WH, Roa WH, Ely L. Effervescent powders for inhalation. US 2007/0031490 A1. 2007.
18. L Ely W Roa WH Finlay R Löbenberg 2007 Effervescent dry powder for respiratory drug delivery Eur J Pharm Biopharm 65 346 53 17156987 10.1016/j.ejpb.2006.10.021 1:CAS:528:DC%2BD2sXisVCgsLs%3D
19. S Azarmi R Löbenberg WH Roa S Tai WH Finlay 2008 Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles Drug Dev Ind Pharm 34 943 7 18800255 10.1080/03639040802149079 1:CAS:528:DC%2BD1cXhtFais7%2FI
20. Finlay W, Orszanska H. Respirable dried powder formulation comprising drug loaded nanoparticles. WO 2006/130943 A1. 2006.
21. S Azarmi X Tao H Chen Z Wang WH Finlay R Löbenberg WH Roa 2006 Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles Int J Pharm 319 155 61 16713150 10.1016/j.ijpharm.2006.03.052 1:CAS:528:DC%2BD28XmvFKgu7g%3D (Pubitemid 44051806)
22. Finlay WH, Roa W, Loebenberg R. Formulation of powder containing nanoparticles for aerosol delivery to the lungs. US 2005/0019270 A1. 2005.
23. MM Bailey EM Gorman EJ Munson C Berkland 2008 Pure insulin nanoparticle agglomerates for pulmonary delivery Langmuir 24 13614 20 18959432 10.1021/la802405p 1:CAS:528:DC%2BD1cXhtlSqtb3O
24. N El-Gendy EM Gorman EJ Munson C Berkland 2009 Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution J Pharm Sci 98 2731 46 19130469 10.1002/jps.21630 1:CAS:528:DC%2BD1MXns1eqsbc%3D
25. C Plumley EM Gorman N El-Gendy CR Bybee EJ Munson C Berkland 2009 Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy Int J Pharm 369 136 43 19015016 10.1016/j.ijpharm.2008.10.016 1:CAS:528:DC%2BD1MXisVCgsrY%3D
26. N El-Gendy C Berkland 2009 Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration Pharm Res 26 1752 63 19415471 10.1007/s11095-009-9886-2 1:CAS:528:DC%2BD1MXltlylsrg%3D
27. El-Gendy N, Berkland C. Combination nanoparticle agglomerates of fluticasone propionate and albuterol sulphate. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory drug delivery 2010. River Grove: Davis Healthcare International; 2010. p. 819-24.
28. F Iskandar W Lenggoro B Xia K Okuyama 2001 Functional nanostructured silica powders derived from colloidal suspensions by sol spraying J Nanopart Res 3 263 70 10.1023/A:1017592817667 1:CAS:528:DC%2BD3MXotlGmuro%3D
29. H Chiou H-K Chan D Heng RK Prud'homme JA Raper 2008 A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation J Aerosol Sci 39 500 9 10.1016/j.jaerosci.2008.02.002 1:CAS:528:DC%2BD1cXmtlCmu7Y%3D
30. H Chiou L Li T Hu H-K Chan J-F Chen J Yun 2007 Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation Int J Pharm 331 93 8 17052870 10.1016/j.ijpharm.2006.09.022 1:CAS:528: DC%2BD2sXht1GisLY%3D (Pubitemid 46176506)
31. Glover WJ, Wan E, Yun JS, Chen J. A process for making micro-sized protein particles. WO 2009/020434 A1. 2009.
32. Berkland CJ, Shi L. Nanoclusters for delivery of therapeutics. US 7651770 B2. 2010.
33. J-F Chen M-Y Zhou L Shao Y-Y Wang J Yun NYK Chew H-K Chan 2004 Feasibility of preparing nanodrugs by high-gravity reactive precipitation Int J Pharm 269 267 74 14698598 10.1016/j.ijpharm.2003.09.044 1:CAS:528: DC%2BD3sXpvFekurY%3D (Pubitemid 38032839)
34. T Hu H Chiou H-K Chan J-F Chen J Yun 2008 Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation J Pharm Sci 97 944 9 17722000 10.1002/jps.21026 1:CAS:528:DC%2BD1cXhvFaksLY%3D (Pubitemid 351293893)
35. Instruction Manual ULTRA plus Field Emission Scanning Electron Microscope, Carl Zeiss NTS GmBH, Oberkochen, Germany, 2008.
36. M Kumon PCL Kwok H Adi D Heng H-K Chan 2010 Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur J Pharm Sci 40 16 24 20172026 10.1016/j.ejps.2010.02.004 1:CAS:528: DC%2BC3cXks1Ghsbw%3D
37. British Pharmacopoeia Appendix XII C, Spottiswoode, London, 2010.
38. AR Clark AM Hollingworth 1993 The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-Implications for in vitro testing J Aerosol Med 6 99 110 10146277 10.1089/jam.1993.6.99 1:STN:280:DyaK2cbgsFGhsQ%3D%3D (Pubitemid 23231366)
39. 2-agonists: Efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD Curr Med Res Opin 23 2405 13 20350055 10.1185/030079907X219698 1:CAS:528:DC%2BD2sXhtlektLzE (Pubitemid 350033442)
40. T Srichana GP Martin C Marriott 1998 Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro Eur J Pharm Sci 7 73 80 9845780 10.1016/S0928-0987(98)00008-6 1:CAS:528:DyaK1cXnvVSrsb8%3D (Pubitemid 29056229)
41. C Weiler M Egen M Trunk P Langguth 2010 Force control and powder dispersibility of spray dried particles for inhalation J Pharm Sci 99 303 16 19533606 10.1002/jps.21849 1:CAS:528:DC%2BD1MXhsVyls7zP
42. D Heng P Tang JM Cairney H-K Chan DJ Cutler R Salama J Yun 2007 Focused-ion-beam milling: a novel approach to probing the interior of particles used for inhalation aerosols Pharm Res 24 1608 17 17404810 10.1007/s11095-007- 9276-6 1:CAS:528:DC%2BD2sXosVKgsbg%3D (Pubitemid 47206609)
43. H Adi PM Young H-K Chan H Agus D Traini 2010 Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease Eur J Pharm Sci 40 239 47 20371286 10.1016/j.ejps.2010.03.020 1:CAS:528:DC%2BC3cXmsVCqsr8%3D